Skip to main content Skip to navigation
Purified Mouse Anti-Human CD317 (BST2)
568105Image1.png

Multiparameter flow cytometric analysis of CD317 (BST2) expression on Human peripheral blood leucocyte populations. Human whole blood was labeled with either Purified Mouse IgG2a, κ Isotype Control (Cat. No. 556651; Left Plot) or Purified Mouse Anti-Human CD317 (BST2) antibody (Cat. No. 568105; Right Plot) at 0.5 μg/test. The cells were further stained with PE Goat Anti-Mouse Ig  (Cat. No. 550589) as the secondary antibody. Erythrocytes were lysed with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899). The bivariate pseudocolor density plot showing the correlated expression of CD317 (BST2) [or Ig Isotype control staining] versus side light-scatter (SSC-A) signals was derived from gated events with the forward and side light-scattering characteristics of viable leucocyte populations. Flow cytometric analysis was performed using a BD LSRFortessa™ Cell Analyzer System X-20 Flow Cytometer System. Data shown on this Technical Data Sheet are not lot specific.

568105_2.png

Multiparameter flow cytometric analysis of CD317 (BST2) expression on Human peripheral blood leucocyte populations. Human whole blood was labeled with either Purified Mouse IgG2a, κ Isotype Control (Cat. No. 556651; Left Plot) or Purified Mouse Anti-Human CD317 (BST2) antibody (Cat. No. 568105; Right Plot) at 0.5 μg/test. The cells were further stained with PE Goat Anti-Mouse Ig  (Cat. No. 550589) as the secondary antibody. Erythrocytes were lysed with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899). The bivariate pseudocolor density plot showing the correlated expression of CD317 (BST2) [or Ig Isotype control staining] versus side light-scatter (SSC-A) signals was derived from gated events with the forward and side light-scattering characteristics of viable leucocyte populations. Flow cytometric analysis was performed using a BD LSRFortessa™ Cell Analyzer System X-20 Flow Cytometer System. Data shown on this Technical Data Sheet are not lot specific.

Multiparameter flow cytometric analysis of CD317 (BST2) expression on Human peripheral blood leucocyte populations. Human whole blood was labeled with either Purified Mouse IgG2a, κ Isotype Control (Cat. No. 556651; Left Plot) or Purified Mouse Anti-Human CD317 (BST2) antibody (Cat. No. 568105; Right Plot) at 0.5 μg/test. The cells were further stained with PE Goat Anti-Mouse Ig  (Cat. No. 550589) as the secondary antibody. Erythrocytes were lysed with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899). The bivariate pseudocolor density plot showing the correlated expression of CD317 (BST2) [or Ig Isotype control staining] versus side light-scatter (SSC-A) signals was derived from gated events with the forward and side light-scattering characteristics of viable leucocyte populations. Flow cytometric analysis was performed using a BD LSRFortessa™ Cell Analyzer System X-20 Flow Cytometer System. Data shown on this Technical Data Sheet are not lot specific.

Multiparameter flow cytometric analysis of CD317 (BST2) expression on Human peripheral blood leucocyte populations. Human whole blood was labeled with either Purified Mouse IgG2a, κ Isotype Control (Cat. No. 556651; Left Plot) or Purified Mouse Anti-Human CD317 (BST2) antibody (Cat. No. 568105; Right Plot) at 0.5 μg/test. The cells were further stained with PE Goat Anti-Mouse Ig  (Cat. No. 550589) as the secondary antibody. Erythrocytes were lysed with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899). The bivariate pseudocolor density plot showing the correlated expression of CD317 (BST2) [or Ig Isotype control staining] versus side light-scatter (SSC-A) signals was derived from gated events with the forward and side light-scattering characteristics of viable leucocyte populations. Flow cytometric analysis was performed using a BD LSRFortessa™ Cell Analyzer System X-20 Flow Cytometer System. Data shown on this Technical Data Sheet are not lot specific.

Product Details
Down Arrow Up Arrow


BD Pharmingen™
BST2; BST-2; bone marrow stromal antigen 2; HM1.24 antigen; Tetherin
Human (QC Testing), Rhesus, Cynomolgus, Baboon (Tested in Development)
Mouse BALB/c IgG2a, κ
Human KPC-32 Plasma Cell Line
Flow cytometry (Routinely Tested)
0.5 mg/ml
VIII 80114
AB_3684038
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Product Notices

  1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  2. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  3. Sodium azide is a reversible inhibitor of oxidative metabolism; therefore, antibody preparations containing this preservative agent must not be used in cell cultures nor injected into animals. Sodium azide may be removed by washing stained cells or plate-bound antibody or dialyzing soluble antibody in sodium azide-free buffer. Since endotoxin may also affect the results of functional studies, we recommend the NA/LE (No Azide/Low Endotoxin) antibody format, if available, for in vitro and in vivo use.
  4. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
  5. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
  6. An isotype control should be used at the same concentration as the antibody of interest.
  7. Species cross-reactivity detected in product development may not have been confirmed on every format and/or application.
568105 Rev. 1
Antibody Details
Down Arrow Up Arrow
Y129

The Y129 monoclonal antibody specifically binds to CD317 which is also known as Bone marrow stromal antigen 2 (BST2). CD317 is a type II transmembrane glycoprotein that belongs to the Tetherin family. CD317 is an interferon (IFN)-induced protein that is expressed on monocytes, granulocytes, dendritic cells, B lymphoblasts, plasma cells, T cells, natural killer (NK) cells, stromal cells and myeloma cells. CD317 is expressed by nonhematopoietic cells including cells within solid tumors derived from breast, lung and kidney. CD317 may be involved in the interactions between bone marrow stromal cells and lymphocytes. It is likewise known as Tetherin and reportedly blocks the release of some enveloped viruses by tethering virions to infected cell membranes. CD317 stimulates signaling by CD85g (ILT7) and may provide negative feedback for interferon (IFN) production by plasmacytoid dendritic cells during viral infections.

568105 Rev. 1
Format Details
Down Arrow Up Arrow
Purified
Tissue culture supernatant is purified by either protein A/G or affinity purification methods. Both methods yield antibody in solution that is free of most other soluble proteins, lipids, etc. This format provides pure antibody that is suitable for a number of downstream applications including: secondary labeling for flow cytometry or microscopy, ELISA, Western blot, etc.
Purified
568105 Rev.1
Citations & References
Down Arrow Up Arrow
View product citations for antibody "568105" on CiteAb

Development References (11)

  1. Buckley CD, Halder S, Hardie D, et al. Report on antibodies submitted to the stromal cell section of HLDA8.. Cell Immunol. 236(1-2):29-41. (Immunogen). View Reference
  2. Gong S, Osei ES, Kaplan D, Chen YH, Meyerson H. CD317 is over-expressed in B-cell chronic lymphocytic leukemia, but not B-cell acute lymphoblastic leukemia.. Int J Clin Exp Pathol. 2015; 8(2):1613-21. (Biology). View Reference
  3. Goto T, Kennel SJ, Abe M, et al. A novel membrane antigen selectively expressed on terminally differentiated human B cells.. Blood. 1994; 84(6):1922-30. (Immunogen). View Reference
  4. Harada T, Ozaki S. Targeted therapy for HM1.24 (CD317) on multiple myeloma cells.. Biomed Res Int. 2014; 2014:965384. (Clone-specific: Functional assay, In vivo exacerbation, Radioimmunoassay). View Reference
  5. Mahauad-Fernandez WD, Okeoma CM. The role of BST-2/Tetherin in host protection and disease manifestation.. Immun Inflamm Dis. 2016; 4(1):4-23. (Biology). View Reference
  6. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.. Nature. 2008; 451(7177):425-30. (Biology). View Reference
  7. Serra-Moreno R, Jia B, Breed M, Alvarez X, Evans DT. Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic nef-deleted SIV.. Cell Host Microbe. 2011; 9(1):46-57. (Clone-specific: Immunofluorescence). View Reference
  8. Staudinger M, Glorius P, Burger R, et al. The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.. Blood Cancer J. 2014; 4:e219. (Biology). View Reference
  9. Van Damme N, Goff D, Katsura C, et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.. Cell Host Microbe. 2008; 3(4):245-52. (Clone-specific: Flow cytometry). View Reference
  10. Vidal-Laliena M, Romero X, March S, Requena V, Petriz J, Engel P. Characterization of antibodies submitted to the B cell section of the 8th Human Leukocyte Differentiation Antigens Workshop by flow cytometry and immunohistochemistry. Cell Immunol. 2005; 236(1-2):6-16. (Clone-specific: Calcium Flux, Flow cytometry). View Reference
  11. Wiche Salinas TR, Gosselin A, Raymond Marchand L, et al. IL-17A reprograms intestinal epithelial cells to facilitate HIV-1 replication and outgrowth in CD4+ T cells.. iScience. 2021; 24(11):103225. (Clone-specific: Flow cytometry). View Reference
View All (11) View Less
568105 Rev. 1

Please refer to Support Documents for Quality Certificates

 

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

 

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.